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Background: The global gene regulator Special AT-rich sequence-binding protein1 (SATB1) has been reported to
reprogramme tumour cells into a more malignant phenotype and associate with poor clinical outcome in several
cancer forms. In this study, we investigated the molecular correlates and prognostic impact of SATB1 expression in
human epithelial ovarian cancer (EOC).
Findings: Immunohistochemical expression of SATB1 was examined in tissue microarrays with tumours from 151
incident EOC cases from two prospective, population-based cohorts. Benign-appearing fallopian tube epithelium
from 32 cases was also analyzed. A multiplier of nuclear fraction and staining intensity of SATB1 was calculated.
While barely expressed in tubal epithelium, nuclear SATB1 expression was denoted in 35/151 (23.2%) EOC cases.
Spearman´s Rho test revealed an inverse correlation between SATB1 expression and histological grade (R = -0.22,
p = 0.006) and a positive correlation with expression of dachshund 2 protein (R = 0.28, p = 0.001), phosphorylated
Chek1 (R = 0.26, p = 0.002) and minichromosome maintenance protein 3 (R = 0.17, p = 0.042). Univariable Cox
regression analysis revealed that SATB1 expression, while not prognostic in the full cohort, was associated with a
reduced ovarian cancer-specific survival and 5-year overall survival in high grade tumours (n = 105) (HR = 2.14 and
HR= 1.96, respectively). This association remained significant in multivariable analysis, adjusted for age and clinical
stage (HR = 2.20 and HR= 2.06, respectively).
Conclusions: These results demonstrate that SATB1 expression is an independent factor of poor prognosis in high
grade EOC and correlates in vivo with cellular processes involved in the maintenance of DNA integrity. The
functional basis for these observations merits further investigation.
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Background
The T-lineage enriched global chromatin organizer and
epigenetic regulator Special AT-rich sequence-binding
protein 1(SATB1) [1,2] has been reported to promote a
metastatic phenotype and correlate with poor prognosis
in breast cancer [3]. SATB1 expression has also been
associated with unfavourable clinicopathological charac-
teristics and poor prognosis in gastric, liver and colo-
rectal cancer, and glioma [4-9]. In a recent study on
epithelial ovarian cancer (EOC), SATB1 expression was* Correspondence: bjorn.nodin@med.lu.se
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reproduction in any medium, provided the orfound to be up-regulated both at the mRNA and protein
level in EOC (n = 91) compared to borderline tumours
and normal ovarian tissue [10]. High SATB1 expression
was also found to correlate with increased FIGO stage,
lymph node metastasis and reduced overall survival, but
it was not reported whether SATB1 was an independent
prognostic factor [10]. In the present study, immunohis-
tochemical SATB1 expression was examined in primary
tumours from 151 incident cases of EOC from two
Swedish population-based cohort studies, and correlated
with clinicopathological factors, molecular parameters,
and survival. A subset of concomitantly sampled benign-
appearing fallopian tubes (n = 32) was also analyzed for
SATB1 expression.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Immunohistochemical images of SATB1 staining in fallopian tubes and ovarian cancer. Images (20X magnification)
demonstrating negative immunohistochemical expression of SATB1 in (A, B) fallopian tubes, and different fractions and staining intensities in EOC
ranging from (C) negative, (D-G) weak to moderate intensity in increasing fractions and (H) strong intensity in the majority of tumour cells.
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The study cohort is a merge of incident cases of epithe-
lial ovarian cancers in the Malmö Diet and Cancer Study
and Malmö Preventive Project up until 31 Dec 2007, as
previously described [11-15]. Information on vital statusand cause of death was obtained from the Swedish
Cause of Death Registry up until 30 June 2012. After a
median follow-up of 3.00 years (range 0–24.63), 122
patients (79.2%) were dead, 112 (72.3%) from ovarian
cancer, and 32 (20.8%) were alive. All tumors were re-
Figure 2 Distribution of SATB1 staining in primary tumours. Bar
chart visualizing the relationship of nuclear SATB1 staining intensity
with the estimated proportion of tumour cells expressing SATB1.
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logical grading performed according to a universal sys-
tem [16].
Information regarding clinical stage was obtained from
the medical charts, following the standardized FIGO clas-
sification of tumor staging. Information on residual tumor
after surgery was not available. Standard adjuvant therapy
was platinum-based chemotherapy, from the 1990s given
in combination with paclitaxel. Ethical permission was
obtained from the Ethics Committee at Lund University.
Study design, methodological and technical considera-
tions, as well as data presentation were based on the
REMARK criteria [17]. Tissue microarrays (TMAs) had
been constructed as previously described [11], whereby
two 1.0 mm cores were taken from viable, non-necrotic
primary tumor areas. Fallopian tubes with no evidence of
histological disease were also sampled from 38 cases. For
immunohistochemical analysis, 4 μm TMA-sections were
automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an Auto-
stainer Plus (DAKO, Glostrup, Denmark) with a monoclo-
nal anti-SATB1 antibody (Clone EPR3895, Epitomics,
Burlingame, CA, USA) diluted 1:100. The specificity of
the antibody towards SATB1 has been demonstrated pre-
viously[8]. The estimated percentage of cells with nuclear
SATB1 expression was recorded, as well as the predomin-
ant nuclear intensity, denoted as negative (0), weak (1),
moderate (2) or strong (3). A combined nuclear score was
constructed by multiplying fraction and intensity. Stromal
lymphocytes served as positive internal controls and nor-
mal colorectal mucosa as negative control [8,9]. Immuno-
histochemical staining for androgen, estrogen and
progesterone receptors (AR, ER and PR), RNA-binding
motif protein 3 (RBM3), minichromosome maintenance 3
protein (MCM3), Chek1, Chek2, Ki67 and Dachshund 2
protein (DACH2) was performed as previously described
[11-14].Spearman´s Rho test was used for comparison of
SATB1 expression (nuclear score) with clinicopathologi-
cal and tumour biological factors. Kaplan-Meier analysis
and log rank test were applied to illustrate differences in
ovarian cancer specific survival (OCSS) and 5-year over-
all survival (OS) in strata according to negative (0-1%)
and positive (>1%) SATB1 expression. Cox regression
proportional hazards models were used for estimation of
hazard ratios (HRs) for death from ovarian cancer or
overall causes within 5 years according to negative and
positive SATB1 expression in both uni- and multivari-
able analysis in high-grade tumours, adjusted for age
and clinical stage. All calculations were performed using
IBM SPSS Statistics Version 20 (SPSS Inc, Chicago, IL).
All statistical tests were two-sided and a p value < 0.05
was considered statistically significant.
Results
In 32/38 (84.2%) evaluable cases of benign-appearing fal-
lopian tubal epithelium, no or very low levels of SATB1
expression could be detected (Figure 1 A, B). In primary
EOC, positive SATB1 expression was denoted in 35/151
(23.2%) evaluable cases, predominantly in fractions
<50% and intensities ranging from weak to moderate
(Figure 1 C-H and Figure 2), and always exceeding tubal
expression. The associations of SATB1 expression with
established clinicpathological factors and investigative
markers is shown in Table 1. SATB1 expression was
significantly associated with lower histological grade
(Spearman´s Rho= -0.22, p= 0.006) but not with age or
clinical stage. SATB1 expression did not differ by
histological subtype (data not shown). There was no sig-
nificant correlation between SATB1 expression and expres-
sion of AR, ER, PR, Ki67, Chek1, Chek2, pChek2 or
RBM3. A positive correlation was seen between SATB1
and DACH2 expression (R=0.28, p= 0.001), pChek1
(R=0.26, p = 0.001), and MCM3 expression (R=0.17,
p= 0.042).
Kaplan-Meier analysis revealed no significant association
of SATB1 expression with OCSS or OS in the full cohort
(data not shown) but stratified analysis according to
tumour grade revealed that positive SATB1 expression
was a significant factor of poor prognosis in high grade
tumours (n=105), regardless of histological subtype (log-
rank p=0.004 for OCSS and logrank p=0.015 for 5-year
OS, (Figure 3 A-B). These associations were confirmed in
univariable and multivariable Cox regression analysis,
adjusted for age and clinical stage (Table 2). SATB1 ex-
pression was not prognostic in low-grade tumours or in
subgroups according to histological type (data not shown).
Discussion
The results from this study demonstrate that SATB1 ex-
pression is an independent factor of poor prognosis in
Table 1 Associations of SATB1 expression with
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R= Spearman´s correlation coefficient, p = p-value, n = number of cases
available for analysis. ER = estrogen receptor, PR = progesterone receptor,
AR =Androgen receptor. *significance at 5% level, ** significance at 1% level.
The analyses are based on multipliers of staining intensity and fraction
(nuclear score) for expression of SATB1, DACH2, RBM3, Chek1, Chek2 and
MCM3 and categories of nuclear fraction for expression of Ki67, AR, ER, and
PR.
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subtype. These findings are in line with previous studies
on the prognostic value of SATB1 expression in EOC and
several other cancer forms [3-7,10] and thus further sup-
port the notion that the regulatory activities of SATB1 in
cancer preferentially seem to confer a more malignant
phenotype [18]. In the present study, SATB1 expression
was found to be up-regulated in EOC compared to tubal
epithelium, from which a proportion of serous carcinomas
are though to arise [19]. These findings further underline
a role for SATB1 in ovarian carcinogenesis. No associa-
tions were found between SATB1 expression and expres-
sion of hormone receptors. In breast cancer, one study
found SATB1 mRNA expression levels to be higher in ER
negative compared to ER positive tumours [20] and in an-
other study, high SATB1 mRNA expression was found to
correlate with an improved prognosis in ER positive but
not in ER negative tumours, although this did not remain
significant in multivariable analysis [21]. Notably, both of
these studies relied on gene expression data only [20,21]
and none could confirm the negative prognostic value of
SATB1 expression in breast cancer demonstrated by Han
et al.[3], who found immunohistochemical SATB1 expres-
sion to be an independent factor of poor prognosis [3].
Compared to gene expression analyses, immunohisto-
chemistry has some advantages in biomarker studies since
it allows for quantitative assessment of proteins in a mor-
phological and subcellular context, which might have im-
portant prognostic implications. SATB1 is not only
expressed in tumour cell nuclei, but also in stromal lym-
phocytes, serving as internal staining controls, and our
results demonstrate that the prognostic impact of SATB1
was evident even at low levels of expression. These
Figure 3 Kaplan-Meier estimates of survival according to
SATB1 expression in patients with high-grade tumours. Kaplan
Meier analysis of (A) ovarian cancer specific and (B) 5-year overall
survival in strata according to negative and positive SATB1
expression in patients with high-grade tumours (n = 105).
Table 2 Relative risks of death from ovarian cancer and overa
high-grade tumours
Ovarian cancer specific survival
HR(95%CI) p-value n(eve
Univariable
SATB1 neg 1.00 0.005 87(67
SATB1 pos 2.14(1.26-3.62) 18(18
Multivariable
SATB1 neg 1.00 0.009 82(62
SATB1 pos 2.20(1.21-3.99) 14(14
Cox uni- and multivariable analysis of relative risks of death from ovarian cancer an
carcinomas, irrespective of histological subtype (n = 105). HR =Hazard ratio. Multiva
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immunohistochemical expression of SATB1 was denoted
as being weak in the majority of the analysed breast cancer
samples, and it was demonstrated that even low levels of
SATB1 correlated with poor prognosis [3].
A limitation to the here analyzed cohort is the lack of
information on residual tumour after surgery, and there-
fore, the prognostic value of SATB1 expression in EOC
should be confirmed in studies on tumours for which
this information is available. The inverse correlation be-
tween SATB1 expression and histological grade might
contribute to the lack of prognostic value for SATB1 in
the full cohort. Xiang et al. found no correlation be-
tween SATB1 expression and grade, but a positive asso-
ciation with clinical stage [10].
Notably, the heterogeneity among EOC is not only
reflected in the occurence of different histological sub-
types but also in their mode of progression, i.e. through
a stepwise mutation process (low-grade pathway) or
through greater genetic instability (high-grade pathway)
[22]. Therefore, despite the lack of a more thorough mo-
lecular classification of the here studied tumours, and
the use of a universal rather than subtype-specific grad-
ing system, our results indicate that the tumour-
promoting effects of SATB1 expression in EOC differs
according to mutational status and genetic stability of
the tumours. The associations of SATB1 with expression
of MCM3 and phosphorylated Chek1 imply a link be-
tween SATB1 and maintenance of DNA integrity [13],
and expression of both MCM3 and DACH2 has previ-
ously been demonstrated to correlate with poor progno-
sis in EOC [13,14].
Conclusions
This study provides further evidence of important regu-
latory functions of SATB1 in ovarian carcinogenesis and
progression, and demonstrate SATB1 expression to bell death according to SATB1 expression in patients with
5-year overall survival
nts) HR(95%CI) p-value n(events)
Univariable
) 1,00 0.017 87(60)
) 1.96(1.13-3.42) 18(16)
Multivariable
) 1,00 0.022 82(55)
) 2.06(1.11-3.81) 14(13)
d overall death according to SATB1 expression in patients with high-grade
riable analysis included adjustment for age and clinical stage (1–2 vs 3–4).
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tumours. Future studies should address the mechanistic
basis for these functions in the context of molecular
aberrations and chemotherapy response.
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